o NoneEntity Type
0001641489
VTV Therapeutics Inc.
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 vTv Therapeutics Inc.
Jurisdiction of Incorporation/OrganizationDELAWARE 
Year of Incorporation/Organization
  o Over Five Years Ago
  x Within Last Five Years (Specify Year) 2015
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 vTv Therapeutics Inc. 
Street Address 1Street Address 2
 3980 Premier Drive Suite 310
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 High Point NORTH CAROLINA 27265 336-841-0300 



3. Related Persons
Last NameFirst NameMiddle Name
HolcombeStephen
Street Address 1Street Address 2
3980 Premier DriveSuite 310
CityState/Province/CountryZIP/Postal Code
High PointNORTH CAROLINA27265
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
HowardRudy
Street Address 1Street Address 2
3980 Premier DriveSuite 310
CityState/Province/CountryZIP/Postal Code
High PointNORTH CAROLINA27265
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
KindlerJeffrey
Street Address 1Street Address 2
3980 Premier DriveSuite 310
CityState/Province/CountryZIP/Postal Code
High PointNORTH CAROLINA27265
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
KozlovHersh
Street Address 1Street Address 2
3980 Premier DriveSuite 310
CityState/Province/CountryZIP/Postal Code
High PointNORTH CAROLINA27265
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

 
Last NameFirst NameMiddle Name
FryJohn
Street Address 1Street Address 2
3980 Premier DriveSuite 310
CityState/Province/CountryZIP/Postal Code
High PointNORTH CAROLINA27265
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
SavasPaul
Street Address 1Street Address 2
3980 Premier DriveSuite 310
CityState/Province/CountryZIP/Postal Code
High PointNORTH CAROLINA27265
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
SpiegelNoel
Street Address 1Street Address 2
3980 Premier DriveSuite 310
CityState/Province/CountryZIP/Postal Code
High PointNORTH CAROLINA27265
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
WeinerHoward
Street Address 1Street Address 2
3980 Premier DriveSuite 310
CityState/Province/CountryZIP/Postal Code
High PointNORTH CAROLINA27265
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  x Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2020-01-07 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests x Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities x Option, Warrant or Other Right to Acquire Another Security
o Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
  
(Associated) Broker or Dealer o None(Associated) Broker or Dealer CRD Number o None
  
Street Address 1Street Address 2
  
City State/Province/CountryZIP/Postal Code
   
State(s) of Solicitation o All States
 
 



13. Offering and Sales Amounts
Total Offering Amount $ 10000000 USD o Indefinite
Total Amount Sold $ 2000000 USD 
Total Remaining to be Sold $ 8000000 USD o Indefinite
 
Clarification of Response (if Necessary)
 See the Issuer's Current Reports on Form 8-K filed with the Securities and Exchange Commission on December 23, 2019 and January 7, 2020.


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 0


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 0 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
  


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more vTv Therapeutics Charts.
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more vTv Therapeutics Charts.

Vtv Therapeutics Inc. News

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
Tuesday 19 March 2024 (2 months ago) • PR Newswire (US)
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Wednesday 13 March 2024 (2 months ago) • GlobeNewswire Inc.
Form 3 - Initial statement of beneficial ownership of securities
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)
Form SC 13D - General statement of acquisition of beneficial ownership
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
Tuesday 5 March 2024 (2 months ago) • GlobeNewswire Inc.
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
Saturday 2 March 2024 (2 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Thursday 29 February 2024 (2 months ago) • Edgar (US Regulatory)
Form 424B5 - Prospectus [Rule 424(b)(5)]
Thursday 29 February 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Thursday 29 February 2024 (2 months ago) • Edgar (US Regulatory)
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
Thursday 29 February 2024 (2 months ago) • GlobeNewswire Inc.
CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE
Friday 23 February 2024 (2 months ago) • PR Newswire (US)

More Vtv Therapeutics Inc. News Articles